December 5, 2014 (Update) - On July 22, 2014, Puma Biotechnology Inc announced positive top line results from the Phase III clinical trial of Puma's investigational breast cancer drug, PB272 (neratinib). Puma Biotechnology Inc said that based on the results from the ExteNET study, Puma plans to file for regulatory approval of neratinib in the extended adjuvant setting in the first half of 2015.

Shares of Puma Biotechnology Inc (NYSE:PBYI) jumped from $59.03 per share on July 22, 2014, to $233.43 per share on July 23, 2014 and continued to increase to as high as $275.07 per share in September 2014.

Then on December 2, 2014, Puma Biotechnology Inc announced that it intends to delay its proposed timeline for filing the new drug application (NDA) until the first quarter of 2016. Puma Biotechnology Inc said that it originally focused on the proposed clinical indication of HER2-positive metastatic breast cancer and now plans to apply first for extended adjuvant HER2-positive early stage breast cancer

Share of Puma Biotechnology Inc (NYSE:PBYI) declined from $228.82 per share on December 2, 2014, to $189.51 per share on December 3, 2014.

June 3, 2014 (Shareholders Foundation) - An investigation on behalf of investors of Puma Biotechnology Inc (NYSE:PBYI) shares over potential securities laws violations by Puma Biotechnology and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Puma Biotechnology Inc (NYSE:PBYI) concerning whether a series of statements by Puma Biotechnology regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On December 4, 2013, Puma Biotechnology Inc reported announced top line results from the Phase II clinical trial of Puma's investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer

Shares of Puma Biotechnology Inc (NYSE:PBYI) jumped from $46.21 per share on December 4, 2014, to $77.70 per share on December 5, 2014 and continued to increase to as high as $139.92 per share in late January 2014.

On March 3, 2014, Puma Biotechnology Inc reportd its fourth quarter and full year 2013 financial results. Among other things, Puma Biotechnology Inc (NYSE:PBYI) reported that its Net Loss of $74.35 million in 2012 declined to a Net Loss of $54.66 million in 2013.

On May 12, 2014, Puma Biotechnology Inc reported its first quarter 2014 financial results. Among other things, Puma Biotechnology Incs first quarter Net Loss increase from $1.78 million in 2013 to $19.79 million in 2014.

On June 1, 2014, Puma Biotechnology Inc announced that announced that it presented results at the American Society of Clinical Oncology from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) for the treatment of HER2 positive metastatic breast cancer that has metastasized to the brain.

Share of Puma Biotechnology Inc (NYSE:PBYI) declined from almost $140 per share in late January 2014 to as low as $57.06 per share on June 2, 2014.